Clinical Trials List
2026-05-01 - 2033-12-31
Phase III
Recruiting6
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/01
Investigators and Locations
Co-Principal Investigator
- MING YAO Division of Hematology & Oncology
- CHIA-JU LIU Division of Radiology
- Sheng-chieh Chou Division of Hematology & Oncology
- 林耘曲 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 劉鴻霖 Division of Hematology & Oncology
- 馬銘君 Division of Hematology & Oncology
- Hong jie Chen Division of Nuclear Medicine
- 李建霖 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張力常 Division of Hematology & Oncology
- Sin-Syue Li Division of Hematology & Oncology
- Ya-Ting Hsu Division of Hematology & Oncology
- Ya-Ping Chen Division of Hematology & Oncology
- 傅蓓安 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- PO-WEI LIAO Division of Hematology & Oncology
- 鄧齡喬 Division of Hematology & Oncology
- CHENG-HSIEN LIN Division of Hematology & Oncology
- PO-HSIEN LI Division of Hematology & Oncology
- Tsung -Chih Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ching Yun Hsieh Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- 王幸婷 Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Sheng-Hsuan Chien Division of Hematology & Oncology
- 陳志丞 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
700 participants
